[
  {
    "ts": "2025-12-22T01:09:05+00:00",
    "headline": "Reassessing Astellas Pharma (TSE:4503) Valuation After Positive PADCEV-Keytruda Phase 3 Bladder Cancer Results",
    "summary": "Astellas Pharma (TSE:4503) just cleared an important milestone with Pfizer, as their PADCEV plus Keytruda combo hit primary and key secondary endpoints in a Phase 3 bladder cancer trial, sharpening the stock's long term growth story. See our latest analysis for Astellas Pharma. The market has been warming to that oncology story, with Astellas Pharma’s share price delivering a strong year to date return of 37.52 percent and a 1 year total shareholder return of 42.97 percent, underpinned by a...",
    "url": "https://finance.yahoo.com/news/reassessing-astellas-pharma-tse-4503-010905309.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "80294591-caf0-3a07-b84c-e48e6b7368bf",
      "content": {
        "id": "80294591-caf0-3a07-b84c-e48e6b7368bf",
        "contentType": "STORY",
        "title": "Reassessing Astellas Pharma (TSE:4503) Valuation After Positive PADCEV-Keytruda Phase 3 Bladder Cancer Results",
        "description": "",
        "summary": "Astellas Pharma (TSE:4503) just cleared an important milestone with Pfizer, as their PADCEV plus Keytruda combo hit primary and key secondary endpoints in a Phase 3 bladder cancer trial, sharpening the stock's long term growth story. See our latest analysis for Astellas Pharma. The market has been warming to that oncology story, with Astellas Pharma’s share price delivering a strong year to date return of 37.52 percent and a 1 year total shareholder return of 42.97 percent, underpinned by a...",
        "pubDate": "2025-12-22T01:09:05Z",
        "displayTime": "2025-12-22T01:09:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zGlsZQabpZKiecAhuIM4vQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/whFiaQBgqA5L2OMhKv37Ig--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/reassessing-astellas-pharma-tse-4503-010905309.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/reassessing-astellas-pharma-tse-4503-010905309.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALPMF"
            },
            {
              "symbol": "4503"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T08:58:00+00:00",
    "headline": "Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?",
    "summary": "Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader.",
    "url": "https://www.fool.com/investing/2025/12/22/forget-novo-nordisk-buy-high-yield-drug-stock/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "2c160554-0225-3523-ac6e-41ac27dc9837",
      "content": {
        "id": "2c160554-0225-3523-ac6e-41ac27dc9837",
        "contentType": "STORY",
        "title": "Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?",
        "description": "",
        "summary": "Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader.",
        "pubDate": "2025-12-22T08:58:00Z",
        "displayTime": "2025-12-22T08:58:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/34be29d992e20b626208f7610cd6ad29",
          "originalWidth": 1200,
          "originalHeight": 801,
          "caption": "A medical professional filling a needle from a bottle of medicine.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4FLKocTE8Dy4an3gq.W46A--~B/aD04MDE7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/34be29d992e20b626208f7610cd6ad29.cf.webp",
              "width": 1200,
              "height": 801,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OjZI_UgWLI8P7SE8GyR7Cw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/34be29d992e20b626208f7610cd6ad29.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/22/forget-novo-nordisk-buy-high-yield-drug-stock/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/forget-novo-nordisk-buy-magnificent-085800517.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T11:07:10+00:00",
    "headline": "Positive Phase 3 PADCEV–Keytruda Bladder Cancer Data Could Be A Game Changer For Astellas Pharma (TSE:4503)",
    "summary": "In December 2025, Astellas Pharma and Pfizer reported that their Phase 3 EV-304 trial of PADCEV plus Keytruda in muscle-invasive bladder cancer achieved statistically significant improvements in event-free and overall survival, with higher pathologic complete response rates and a safety profile consistent with prior data. The strength of these pivotal results could meaningfully reinforce PADCEV’s role within Astellas’ oncology portfolio, particularly in earlier-stage bladder cancer where...",
    "url": "https://finance.yahoo.com/news/positive-phase-3-padcev-keytruda-110710750.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "7c7fd859-58c5-3d7e-b7fc-a205d3c6f25d",
      "content": {
        "id": "7c7fd859-58c5-3d7e-b7fc-a205d3c6f25d",
        "contentType": "STORY",
        "title": "Positive Phase 3 PADCEV–Keytruda Bladder Cancer Data Could Be A Game Changer For Astellas Pharma (TSE:4503)",
        "description": "",
        "summary": "In December 2025, Astellas Pharma and Pfizer reported that their Phase 3 EV-304 trial of PADCEV plus Keytruda in muscle-invasive bladder cancer achieved statistically significant improvements in event-free and overall survival, with higher pathologic complete response rates and a safety profile consistent with prior data. The strength of these pivotal results could meaningfully reinforce PADCEV’s role within Astellas’ oncology portfolio, particularly in earlier-stage bladder cancer where...",
        "pubDate": "2025-12-22T11:07:10Z",
        "displayTime": "2025-12-22T11:07:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zGlsZQabpZKiecAhuIM4vQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/whFiaQBgqA5L2OMhKv37Ig--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/positive-phase-3-padcev-keytruda-110710750.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/positive-phase-3-padcev-keytruda-110710750.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALPMF"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T13:00:00+00:00",
    "headline": "Flagship Pioneering and Repertoire® Immune Medicines Announce Agreement to Identify T Cell-Targeted Immune Medicines for Prostate Cancer Under Strategic Partnership with Pfizer",
    "summary": "Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded Repertoire® Immune Medicines will identify and optimize TCR bispecifics for metastatic prostate cancer.",
    "url": "https://finance.yahoo.com/news/flagship-pioneering-repertoire-immune-medicines-130000322.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "8262610a-528e-3ca1-b486-1421dacadaf5",
      "content": {
        "id": "8262610a-528e-3ca1-b486-1421dacadaf5",
        "contentType": "STORY",
        "title": "Flagship Pioneering and Repertoire® Immune Medicines Announce Agreement to Identify T Cell-Targeted Immune Medicines for Prostate Cancer Under Strategic Partnership with Pfizer",
        "description": "",
        "summary": "Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded Repertoire® Immune Medicines will identify and optimize TCR bispecifics for metastatic prostate cancer.",
        "pubDate": "2025-12-22T13:00:00Z",
        "displayTime": "2025-12-22T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/1a51427c584f846361c98bc2eeb40827",
          "originalWidth": 400,
          "originalHeight": 158,
          "caption": "(PRNewsfoto/Flagship Pioneering)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6rHyG6AtTObFjtqCyV2n.A--~B/aD0xNTg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/1a51427c584f846361c98bc2eeb40827.cf.webp",
              "width": 400,
              "height": 158,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aTDm9ReMs6gjIoaonWAeoA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/1a51427c584f846361c98bc2eeb40827.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/flagship-pioneering-repertoire-immune-medicines-130000322.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/flagship-pioneering-repertoire-immune-medicines-130000322.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]